QIF-T0137
highUCNP-mediated optogenetic dopamine release (980nm)
Tier 3 — Demonstrated (Lab-proven)
Legacy status: DEMONSTRATED
Technique Details
- Tactic
- QIF-N.NM
- Status
- DEMONSTRATED
- Bands
- I0, N1, N2, N3
✚ Therapeutic Application
980nm NIR excitation of NaYF4:Yb/Tm upconversion nanoparticles (UCNPs) injected into VTA. UCNPs emit 450/475nm blue light locally, activating ChR2 channelrhodopsin expressed in dopaminergic neurons via viral vector. Triggers acute dopamine release on millisecond timescale. Requires both genetic modification (ChR2 expression) and NP injection (neurosurgery).
Clinical Analog
Deep brain optogenetic stimulation for Parkinson's disease
Treats
- Parkinson's disease
- depression
- addiction
Neural Impact
4 of 7 neural bands affected
Drag to rotate. Click a region to learn more.
Click or hover over a glowing region to see the attack techniques targeting it and their severity.
Scoring
Validation Status
Theoretical / Not yet validated. This technique has not been independently tested. See the validation dashboard for what has been tested.